Navigation Links
Mount Sinai researchers to test first gene therapy For Alzheimer's patients
Date:11/17/2009

Mount Sinai School of Medicine is one of 12 sites nationwide participating in the first Phase 2 clinical trial to test gene therapy treatment for Alzheimer's disease. The study is the first multicenter neurosurgical intervention in Alzheimer's research in the U.S.

The experimental treatment utilizes a viral-based gene transfer system, CERE-110, that makes Nerve Growth Factor (NGF), a naturally occurring protein that helps maintain nerve cell survival in the brain. CERE-110 has been previously studied in animals, where it reversed brain degeneration in aged monkeys and rats. For this study, CERE-110, will be injected by a neurosurgeon directly into the nucleus basalis of Meynert (NBM) of the brain, an area where neuronal death occurs in Alzheimer's patients.

In animal studies, NGF has been shown to support the survival and function of the neurons that deteriorate in Alzheimer's patients. These neurons produce the chemical acetylcholine, which is important in memory and cognitive function. The hope is that improvement of this system's function may lead to better memory performance in Alzheimer's patients.

A Phase 1 study in Alzheimer's patients has been conducted at Rush University in Chicago and the University of California San Diego, where researchers observed increases in brain metabolism in several cortical regions of the brain at 6- and 12-month follow-up in some of the participants. With follow-up ranging from six months to more than four years post-treatment, there have been no side effects thought to be caused by CERE-110.

Participants in the Phase 2 study will be randomly placed into one of two treatment groups, with half receiving CERE-110 via neurosurgery and half receiving placebo surgery without any cranial injections. Once the study is completed, and if the results are promising, participants in the placebo group will be eligible to be treated with CERE-110. All participants will receive a thorough medical examination and cognitive testing. In addition, participants will be closely monitored by a team of physicians for the duration of the two-year study. Participants will also be encouraged to participate in long-term follow-up.


'/>"/>

Contact: Mount Sinai Press Office
newsnow@mountsinai.org
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Related medicine news :

1. Paramount Acquisition Corp. Announces Chem Rx Expansion into Albany, New York Market
2. Mount Sinai & ENT and Allergy Associates, LLP affiliate to fight cancer
3. Paramount Acquisition Corp. Announces Record Date of October 1, 2007 for Proposed Acquisition of Chem Rx
4. Kaiser Permanente study: Alcohol amount, not type -- wine, beer, liquor -- triggers breast cancer
5. Paramount Acquisition Corp. Files Amendment to Preliminary Proxy Statement for Proposed Acquisition of Chem Rx
6. Fred Hutchinson Cancer Research Center Announces the First-Ever Expedition to an Unclimbed Mountain in the Name of Cancer Research
7. Iron Mountain Acquires RMS Services - USA, Inc.
8. Surge in U.S. Cases of Rocky Mountain Spotted Fever
9. Oregon Scientific to Sponsor First-Ever Rock Concert on Mount Everest
10. Mount Sinai recognized as Center of Excellence for Research in Alzheimers disease
11. Paramount Completes Acquisition of Chem Rx
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... ... 20, 2017 , ... Researchers at the University of Pittsburgh School of Medicine ... that may predict response to a particular class of drugs, not just in patients ... The new findings were published in Proceedings of the National Academy of Science. , ...
(Date:2/20/2017)... , ... February 20, 2017 , ... ... regulated industries, announced Biscom Document Router (BDR), the first IoT device from Biscom ... diagnostics and imaging. Biscom will debut BDR at HIMSS17 and will ...
(Date:2/20/2017)... , ... February 20, 2017 , ... ReportingMD, a Population Health Software Company, is pleased ... the company. The new location will triple the size of the previous location while ... town of Sunapee, NH. , “We are excited to expand our footprint to ...
(Date:2/20/2017)... ... ... Chuck E. Cheese’s® and Center for Autism and Related Disorders (CARD) recently announced ... throughout New England, New York and New Jersey to provide children with autism spectrum ... Chuck E. Cheese’s in a sensory-friendly environment. , After a successful pilot run ...
(Date:2/19/2017)... , ... February 19, 2017 , ... The Citadel’s new ... nursing students, is being led by Amelia Joseph, Ph.D. Joseph was engaged by the ... of the nursing department in early 2016. After a nation-wide search, she was selected ...
Breaking Medicine News(10 mins):
(Date:2/21/2017)... Lexmark International, ... solution that connects Lexmark multifunction printers (MFPs) to EDCO ... leading scanning and indexing software solutions for medical records. ... use a Lexmark MFP at the point of care ... facilities reach HIMSS Stage 7 through state-of-the-art ...
(Date:2/21/2017)... IDAHO FALLS, Idaho , Feb. 21, 2017 /PRNewswire/ ... is has completed a private placement with certain investors ... preferred stock of the Company, Series C Convertible Redeemable ... Stock accrues dividends at an annual rate of 6% ... share.  The Company plans to use the proceeds for ...
(Date:2/21/2017)... SAN JOSE, Calif. , Feb. 21, 2017 ... announced that its Cadence ® Tensilica ® Fusion ... HaLow ™ MAC IP offering. The licensable IP targets ... smart city and industrial applications. M2B leveraged the Fusion F1 ... to run value-added applications like voice trigger, audio identification and ...
Breaking Medicine Technology: